

HARVARD UNIVERSITY  
Office of Technology Development



## Angiogenin as a Potential Therapy for ALS

### Principal Investigator

Guofu Hu, PhD, Assistant Professor of Pathology, Harvard Medical School

### Technology

Angiogenin (ANG), encoding a 14 kDa angiogenic ribonuclease, is the first loss-of-function gene identified in amyotrophic lateral sclerosis (ALS). Since original discovery of ANG as an ALS candidate gene, a total of 15 missense mutations in the coding region of ANG have been identified in 37 of the 4,193 ALS patients. Among them, 10 have been characterized in detail and shown to be **loss-of-function mutations**.

Mouse angiogenin (Ang) protein is strongly expressed in the central nervous system (CNS) during development. Human angiogenin (ANG) protein is strongly expressed in both endothelial cells and motor neurons of normal human fetal and adult spinal cords. ANG has also been shown to stimulate neurite outgrowth and pathfinding of cultured motor neurons and protect stress-induced motor neuron degeneration, whereas the ALS-associated mutant ANG proteins lack these activities.

Preliminary studies carried out in the laboratory of Dr. Guo-fu Hu at Harvard Medical School show that both ANG protein and mRNA are diminished in the spinal cord of human ALS patients and in that of SOD1<sup>G93A</sup> mice that develop ALS-like symptoms. Systemically injected ANG protein **crosses the blood spinal cord barrier** and reaches at the spinal cords of both WT and SOD1<sup>G93A</sup> mice. Intraperitoneal administration of WT ANG protein enhances the motor muscular function of SOD1<sup>G93A</sup> mice and prolongs their survival by 4 weeks. However, the P112L mutant ANG protein (occurred in ALS patients) does not have this activity in SOD1<sup>G93A</sup> mice. Taken together, these results suggest that ANG dysfunction is relevant to ALS pathogenesis.

### Market and Applications

Further efforts are under way at Harvard to determine the role of ANG in motor neuron function, to characterize the involvement of ANG deficiency in ALS pathogenesis, and to optimize the therapeutic activity of ANG in ALS. The hypothesis is that ANG plays a role in motor neuron function and that systemic treatment with ANG protein will improve the motor muscular function of ALS patients and extend their survival. Additionally, the laboratory is testing engineered mutants of the ANG protein, as well as - through a collaboration with a third party - several ANG naturally-occurring splice variants.

### Product Advantages

The Harvard Office of Technology Development (OTD) has been developing a patent application portfolio protecting the use of ANG to treat ALS, emphasizing the unique route of administration which has been shown to cross the blood brain barrier, as well as the engineered mutants which demonstrate increased efficacy over wild type angiogenin in animal models.

### Licensing Opportunity:

This technology is available for worldwide, exclusive licensing. Harvard is looking for development partners who have the knowhow and infrastructure and are willing to commit to the development of ANG for the treatment of ALS.

**Contact:**

Michal Preminger, PhD, MBA  
Sr. Director of Business Development  
Harvard Medical School  
Gordon Hall, Suite 414  
Boston, MA 02115  
(617) 432-3896  
[Michal\\_preminger@harvard.edu](mailto:Michal_preminger@harvard.edu)